By

CR2O
March 26, 2024

InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline

Prepare for a game-changing collaboration! InnoSer and CR2O unveil their strategic partnership, bridging the gap between pre-clinical and clinical research. Join us as we revolutionize drug discovery and development with...
Read More
,
February 15, 2024

Biointelect and CR2O forge new strategic partnership to provide advanced end-to-end commercialisation solutions for the life science sector globally

Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and U.S. firms. The full innovation journey offering for Biointelect, a strategic life...
Read More
,
October 10, 2023

CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift Valley Fever (RVF) in people most at risk of infection

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its partnership with Wageningen Bioveterinary Research (WBVR) to advance WBVR’s vaccine candidate against Rift Valley fever (RVF) through a multi-site Phase...
Read More
,
May 21, 2023

CR2O and Artemis Bioservices successfully continue their well-established cooperation

CR2O is a leading European clinical CRO, specialised in managing and operating early-stage infectious disease clinical trials. Artemis Bioservices is a specialty lab, evaluating viral vaccines and antiviral therapeutics, in...
Read More
March 29, 2023

CR2O and 3D-PharmXchange are celebrating and securing their successful ongoing collaboration

A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a...
Read More
January 26, 2023

Initiation of the First-in-Human trial with Dyadic’s SARS-CoV-2-RBD vaccine candidate DYAI-100

CR2O is happy to announce that the First-in-Human trial with Dyadic’s SARS-CoV-2-RBD vaccine candidate DYAI-100 has started in South Africa. Dyadic International Inc. is a global biotechnology company focused on...
Read More
August 24, 2022

LARISSA consortium reaches milestone: Novel Rift Valley fever vaccine dosed in Phase I human trial

The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA[1] consortium and which started this week, will assess...
Read More
July 29, 2022

First clinical trial authorisation under ECTR is a fact

The clinical trial application of the LARISSA study is the first application submitted successfully by CR2O under the new European Clinical Trial Regulation (ECTR). The ECTR is the new regulation...
Read More
April 22, 2022

Freya Pharma Solutions to start pivotal Phase III study with CR2O as clinical operational partner

Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD). Freya Pharma...
Read More
,
April 19, 2021

Citryll to start first-in-human studies with CR2O as clinical operations partner

Citryll has planned the start of first in human studies for its development candidate CIT-013 for July 2021. CR2O is proud to be a part of Citryll’s exiting journey offering...
Read More
,
1 2